Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Barinthus Biotherapeutics presented updated data from two clinical trials in chronic Hepatitis B at the EASL Congress 2024. The HBV003 trial showed promising results with 67% of participants having HBsAg <10 IU/mL and 19% with undetectable HBsAg. In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, VTP-300 treatment showed a statistically significant difference in HBsAg levels compared to placebo, with 84% of participants discontinuing standard NUC therapy.
June 06, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma, in partnership with Barinthus Biotherapeutics, reported significant results from the IM-PROVE II trial for Hepatitis B treatment. The VTP-300 treatment showed a statistically significant difference in HBsAg levels compared to placebo, with 84% of participants discontinuing standard NUC therapy.
The positive results from the IM-PROVE II trial, showing significant improvements in HBsAg levels and high rates of NUC therapy discontinuation, are likely to boost investor confidence in Arbutus Biopharma's partnership and product pipeline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80